Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biopharmaceutical company Basilea Pharmaceutica has announced that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema, has received approval from the French Health Products Safety Agency.
Subscribe to our email newsletter
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino has received national regulatory approval in France. Basilea will submit a pricing and reimbursement dossier to the French authorities based on the approval.
Toctino (alitretinoin) was developed by Basilea Pharmaceutica International. The French Health Products Safety Agency approved Toctino for the use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.